8 Biotechnology Stocks to Buy Now

8 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

SAGE Therapeutics, Inc. (SAGE) earns a B this week, jumping up from last week’s grade of C. For more information, get Portfolio Grader’s complete analysis of SAGE stock.

The rating of Insys Therapeutics, Inc. (INSY) moves up this week, rising from a B to a A. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets A’s in sales growth, earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of INSY stock.

This is a strong week for Insmed Incorporated (INSM). The company’s rating climbs to B from the previous week’s C. Insmed Incorporated develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.

Advaxis, Inc. (ADXS) improves from a B to a A rating this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ADXS stock.

Lion Biotechnologies, Inc.’s (LBIO) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of LBIO stock.

Affimed N.V. (AFMD) boosts its rating from a C to a B this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of AFMD stock.

Curis, Inc. (CRIS) is seeing ratings go up from a B last week to a A this week. Curis, Inc. is a drug discovery and development company that engages in the research and development of cancer therapeutics. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

This week, GenVec, Inc. (GNVC) pushes up from a C to a B rating. GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of GNVC stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/12/8-biotechnology-stocks-to-buy-now-2/.

©2021 InvestorPlace Media, LLC